We were delighted to talk with Dr Rebecca Bascom (Penn State Hershey Medical Center, Hershey, PA, US) around her study investigating the use of MN-001 in patients with idiopathic pulmonary fibrosis.
‘A Single-Center, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MN-001 (Tipelukast) in Subjects with Idiopathic Pulmonary Fibrosis.‘ was presented at ATS 2021 International Conference, 14-19 May, 2021.
Questions
- Could you give us a brief overview of the challenges in treating idiopathic pulmonary fibrosis (IPF) and how therapy has evolved in recent years? (0:15)
- What is tipelukast and what is its mechanism of action? (0:50)
- What were the aims and design of the first clinical trial of tipelukast? (1:25)
- What were the efficacy and safety findings of the study after 12 months? (2:02)
- What will be the next steps for tipelukast in this indication? (2:39)
Disclosures: Rebecca Bascom has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ATS 2021 (Virtual).
